Caption Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Caption Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.58M	Buy	+29,500	New	+$5.16M	0.03%	505
2025 Q4	–	Sell	-256,200	Closed	-$33.8M	–	1833
2025 Q3	$33.8M	Hold	256,200	–	–	0.26%	77
2025 Q2	$27.2M	Buy	256,200 +95,800	+60%	+$10.4M	0.3%	65
2025 Q1	$19.9M	Buy	+160,400	New	+$20.9M	0.19%	96
2024 Q4	–	Sell	-30,000	Closed	-$3.34M	–	1646
2024 Q3	$3.34M	Buy	30,000 +21,600	+257%	+$2.37M	0.05%	410
2024 Q2	$897K	Buy	+8,400	New	+$924K	0.01%	696
2021 Q4	–	Sell	-45,000	Closed	-$5.86M	–	1762
2021 Q3	$5.86M	Sell	45,000 -20,600	-31%	-$3.11M	0.07%	384
2021 Q2	$11.7M	Buy	+65,600	New	+$11.4M	0.15%	169
2020 Q4	–	Sell	-90,000	Closed	-$12.8M	–	1114
2020 Q3	$12.8M	Buy	+90,000	New	+$11.2M	0.3%	73

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Caption Management's JAZZ Position: Q1 2026 in Review

Caption Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 10,747 shares — an estimated $1.88M sold.

Caption Management first reported a position in JAZZ in Q2 2020 and held it in 6 quarters. The position peaked at $10.8M in Q1 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Caption Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Caption Management sold 10,747 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.88M.
Caption Management first reported a position in Jazz Pharmaceuticals in Q2 2020 and held it in 6 quarters.
Caption Management's Jazz Pharmaceuticals position peaked at $10.8M in Q1 2021.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.